History and future perspectives of treating asthma as a systemic and small airways disease
(2001) In Respiratory Medicine 95(9). p.703-719- Abstract
- Asthma is an inflammatory disorder in which the small airways of the lung play an important role. There is also evidence for the systemic nature of asthma. No current method adequately measures small airways function alone. Therefore, a combination of functional and clinical parameters should be used to ensure that patients with asthma are adequately treated with due consideration of the small airways. Previously therapeutic strategies have focused on bronchodilation and attenuation of airway inflammation.While early oral therapies had the advantage of reaching the small airways and treating the systemic aspect of asthma, they were associated with serious side-effects. Inhaled therapies were therefore developed to limit these effects.... (More)
- Asthma is an inflammatory disorder in which the small airways of the lung play an important role. There is also evidence for the systemic nature of asthma. No current method adequately measures small airways function alone. Therefore, a combination of functional and clinical parameters should be used to ensure that patients with asthma are adequately treated with due consideration of the small airways. Previously therapeutic strategies have focused on bronchodilation and attenuation of airway inflammation.While early oral therapies had the advantage of reaching the small airways and treating the systemic aspect of asthma, they were associated with serious side-effects. Inhaled therapies were therefore developed to limit these effects. However, inhaled therapies have the disadvantage of limited penetration into the peripheral airways and an inability to treat the systemic component of asthma. They are also associated with local and systemic side-effects. The future for asthma treatment is likely to be a systemically administered medication with few side-effects targeting disease-specific mediators. The leukotriene receptor antagonists and anti-IgE monoclonal antibodies are examples of such therapies and the emergence of other new strategies is awaited. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1120298
- author
- Bjermer, Leif LU
- organization
- publishing date
- 2001
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- asthma, inflammation, small airways, systemic, leukotriene receptor antagonists
- in
- Respiratory Medicine
- volume
- 95
- issue
- 9
- pages
- 703 - 719
- publisher
- Elsevier
- external identifiers
-
- pmid:11575891
- scopus:0034803992
- ISSN
- 1532-3064
- DOI
- 10.1053/rmed.2001.1148
- language
- English
- LU publication?
- yes
- id
- 42cbff1f-cd8f-4f27-94d6-16816cc8af4d (old id 1120298)
- date added to LUP
- 2016-04-01 16:05:28
- date last changed
- 2022-01-28 17:11:50
@article{42cbff1f-cd8f-4f27-94d6-16816cc8af4d,
abstract = {{Asthma is an inflammatory disorder in which the small airways of the lung play an important role. There is also evidence for the systemic nature of asthma. No current method adequately measures small airways function alone. Therefore, a combination of functional and clinical parameters should be used to ensure that patients with asthma are adequately treated with due consideration of the small airways. Previously therapeutic strategies have focused on bronchodilation and attenuation of airway inflammation.While early oral therapies had the advantage of reaching the small airways and treating the systemic aspect of asthma, they were associated with serious side-effects. Inhaled therapies were therefore developed to limit these effects. However, inhaled therapies have the disadvantage of limited penetration into the peripheral airways and an inability to treat the systemic component of asthma. They are also associated with local and systemic side-effects. The future for asthma treatment is likely to be a systemically administered medication with few side-effects targeting disease-specific mediators. The leukotriene receptor antagonists and anti-IgE monoclonal antibodies are examples of such therapies and the emergence of other new strategies is awaited.}},
author = {{Bjermer, Leif}},
issn = {{1532-3064}},
keywords = {{asthma; inflammation; small airways; systemic; leukotriene receptor antagonists}},
language = {{eng}},
number = {{9}},
pages = {{703--719}},
publisher = {{Elsevier}},
series = {{Respiratory Medicine}},
title = {{History and future perspectives of treating asthma as a systemic and small airways disease}},
url = {{http://dx.doi.org/10.1053/rmed.2001.1148}},
doi = {{10.1053/rmed.2001.1148}},
volume = {{95}},
year = {{2001}},
}